

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code* Number* Kind Code* (if known)				
	FP17	WO 92/07952 A1	05-14-1992	Immologic Pharmaceutical Corporation; Merck & Co., Inc.		
	<del>FP18</del>	<del>JP 4-303401</del>	<del>09-24-1992</del>	<del>Institut National de la Santé et de la Recherche Médicale</del>		<del>Abs</del>
	FP19	JP 6-506056	07-07-1994	Immologic Pharmaceutical Corporation; Merck & Co., Inc.		Abs
	FP20	WO 02/072631 A2	09-19-2002	Dako A/S; Dynal Biotech ASA		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10782,664
				Filing Date	February 18, 2004
				First Named Inventor	MONTERO-JULIAN, Felix A.
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne NMN
Sheet	1	of	1	Attorney Docket Number	2512.0210001/KWM/ROM (2052-183-NONP)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL55	ALEXANDER, J., et al., "Derivation of HLA-A 11/K <sup>b</sup> Transgenic Mice: Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," <i>J. Immunology</i> 159:4753-4761, The American Association of Immunologists, Bethesda, MD USA (1997)	
	NPL56	CHERSI, A., et al., "Polystyrene Beads Coated with Antibodies Directed to HLA Class I Intracytoplasmic Domain: the Use in Quantitative Measurement of Peptide-HLA Class I Binding by Flow Cytometry", <i>Hum. Immunol.</i> 61:1298-1306, American Society for Histocompatibility and Immunogenetics, Mt. Laurel, NJ USA (2000)	
	<del>NPL57</del>	<del>English language abstract of WO 91/12332 A1</del>	
	NPL58	DENKBERG, G., et al., "Critical Role for CD8 in Binding of MHC Tetramers to TCR: CD8 Antibodies Block Specific Binding of Human Tumor-Specific MHC-Peptide Tetramers to TCR," <i>The Journal of Immunology</i> 167:270-276, The American Association of Immunologists, Bethesda, MD USA (July 2001)	
	NPL59	DENKBERG, G., et al., "Recombinant human single-chain MHC-peptide complexes made from <i>E. coli</i> by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens," <i>Eur. J. Immunol.</i> 30:3522-3532, Wiley-VCH Verlag GmbH, Wiley, Hoboken, NJ USA (2000)	
	NPL60	DENKBERG, G., et al., "Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC restricted T cell receptor-like specificity," <i>PNAS</i> 99:9421-9426, Proceedings of the National Academy of Sciences, Washington, DC USA (2002)	

1026464 1 doc

Examiner Signature	/Marianne DiBrino/	Date Considered	10/29/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.D./